In Vitro Cytotoxicity Activity of Chrysin, Morin and Resveratrol Against MCF-7 Breast Cancer Cell Lines
Arlene Thomas, Niraja Ranadive, Harisha Nayak, Sneha Surendran, Madhavan Nampoothiri, Jayesh Mudgal and Yogendra Nayak
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, India.
Corresponding Author E-mail: yogendra.nayak@manipal.edu
DOI : http://dx.doi.org/10.13005/bbra/2310
ABSTRACT: Pathology of cancer involves abnormal cell growth and metastasis of abnormally grown cells to other systems of body different form their origin. These mass of abnormal cell growth are termed as neoplasm or tumour.Alarming prevalence of cancer states that diagnosis of cancer is crucial in the survival of patients. Early diagnosis and adequate treatment helps in controlling the prognosis of disease. The prevalence witnessed majority of males getting affected by prostate cancer around a 43% and women diagnosed with breast cancer around a 41%. By understanding the magnitude getting affected by breast cancer, we performed tests on the breast cancer cell lines to provide with more novel drug treatments for breast cancer. Cytotoxic activity of flavonoids which includes morin and chrysin, and resveratrol, a natural polyphenol was checked individually on MCF7 breast cancer cell lines through MTT assay and the data was analyzed which could lead to new novel breast cancer treatments.
KEYWORDS: Morin; chrysin; resveratrol; MCF-7; breast cancer; cytotoxicity
Download this article as:Copy the following to cite this article: Thomas A, Ranadive N, Nayak H, Surendran S, Nampoothiri M, Mudgal J, Nayak Y. In Vitro Cytotoxicity Activity of Chrysin, Morin and Resveratrol Against MCF-7 Breast Cancer Cell Lines. Biosci Biotech Res Asia 2016;13(3). |
Copy the following to cite this URL: Thomas A, Ranadive N, Nayak H, Surendran S, Nampoothiri M, Mudgal J, Nayak Y. In Vitro Cytotoxicity Activity of Chrysin, Morin and Resveratrol Against MCF-7 Breast Cancer Cell Lines. Biosci Biotech Res Asia 2016;13(3). Available from: https://www.biotech-asia.org/?p=15685 |